MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 215 filers reported holding MIRATI THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.31 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $568,614 | -2.8% | 15,738 | 0.0% | 0.26% | -45.5% |
| Q1 2023 | $585,139 | +10.3% | 15,738 | +34.5% | 0.48% | +51.4% |
| Q4 2022 | $530,263 | -29.8% | 11,703 | +8.3% | 0.32% | -26.9% |
| Q3 2022 | $755,000 | +1.3% | 10,811 | -2.6% | 0.43% | -4.2% |
| Q2 2022 | $745,000 | -7.1% | 11,096 | +13.8% | 0.45% | -11.8% |
| Q1 2022 | $802,000 | -40.8% | 9,753 | +5.6% | 0.51% | -52.7% |
| Q4 2021 | $1,355,000 | -9.8% | 9,236 | +8.8% | 1.08% | +8.6% |
| Q3 2021 | $1,502,000 | +88.7% | 8,489 | +72.3% | 0.99% | +75.9% |
| Q2 2021 | $796,000 | +8.9% | 4,926 | +15.5% | 0.56% | +4.1% |
| Q1 2021 | $731,000 | -6.6% | 4,266 | +19.7% | 0.54% | +8.6% |
| Q4 2020 | $783,000 | +38.6% | 3,563 | +4.8% | 0.50% | +21.4% |
| Q3 2020 | $565,000 | +38.5% | 3,400 | -4.9% | 0.41% | +21.9% |
| Q2 2020 | $408,000 | – | 3,577 | – | 0.34% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |